VIVO Past Earnings image   This VIVO past earnings page last updated 2/7/2023
VIVO Past Earnings
PeriodPast Earnings DateAdj. EPS
Q4 202211/22/20220.200
Q3 20228/5/20220.160
Q2 20225/6/20220.660
Q1 20222/4/20220.350
Q4 202111/12/20210.230
Q3 20218/6/20210.220
Q2 20215/7/20210.560
Q1 20212/5/20210.650
Q4 202011/13/20200.190
Q3 20208/7/20200.550
Q2 20205/8/20200.230
Q1 20202/7/20200.100
Q4 201911/7/20190.130
Q3 20197/30/20190.160
Q2 20194/30/20190.190
Q1 20191/24/20190.2
Q4 201811/8/20180.2
Q3 20187/31/20180.18
Q2 20184/26/20180.21
Q1 20181/25/20180.15
Q4 201711/9/20170.15
Q3 20177/27/20170.16
Q2 20174/27/20170.22
Q1 20171/25/20170.15
Q4 201611/10/20160.14
Q3 20167/28/20160.21
Q2 20164/28/20160.24
Q1 20161/27/20160.21
Q4 201511/5/20150.2
Q3 20157/23/20150.22
Q2 20154/23/20150.24
Q1 20151/22/20150.19
Q4 201411/6/20140.2
Q3 20147/24/20140.21
Q2 20144/24/20140.24
Q1 20141/22/20140.18
Q4 201311/7/20130.22
Q3 20137/25/20130.24
Q2 20134/25/20130.24
Q1 20131/23/20130.2
Q4 201211/8/20120.21
VIVO Past Revenue
PeriodPast Earnings DateGAAP
Q4 202211/22/20220.07B
Q3 20228/5/20220.07B
Q2 20225/6/20220.11B
Q1 20222/4/20220.09B
Q4 202111/12/20210.08B
Q3 20218/6/20210.06B
Q2 20215/7/20210.09B
Q1 20212/5/20210.09B
Q4 202011/13/20200.06B
Q3 20208/7/20200.08B
Q2 20205/8/20200.06B
Q1 20202/7/20200.05B
Q4 201911/7/20190.05B
Q3 20197/30/20190.05B
Q2 20194/30/20190.05B
Q1 20191/24/201951.48M
Q4 201811/8/201853.10M
Q3 20187/31/201851.74M
Q2 20184/26/201856.45M
Q1 20181/25/201852.28M
Q4 201711/9/201749.70M
Q3 20177/27/201750.14M
Q2 20174/27/201754.12M
Q1 20171/25/201746.81M
Q4 201611/10/201647.07M
Q3 20167/28/201650.66M
Q2 20164/28/201651.26M
Q1 20161/27/201647.16M
Q4 201511/5/201547.07M
Q3 20157/23/201548.20M
Q2 20154/23/201551.55M
Q1 20151/22/201548.01M
Q4 201411/6/201446.69M
Q3 20147/24/201447.20M
Q2 20144/24/201450.10M
Q1 20141/22/201444.80M
Q4 201311/7/201349.00M
Q3 20137/25/201347.10M
Q2 20134/25/201347.30M
Q1 20131/23/201345.40M
Q4 201211/8/201243.70M
Quotes delayed 20 minutes

Email EnvelopeFree VIVO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Meridian Bioscience (VIVO) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

VKTX Past Earnings
VLON Past Earnings
VNDA Past Earnings
VOR Past Earnings
VRAY Past Earnings
VRCA Past Earnings
VRDN Past Earnings
VREX Past Earnings
VRPX Past Earnings
VRTX Past Earnings

VIVO Past Earnings Q&A

What was the best and worst VIVO past earnings results?
For Meridian Bioscience, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest VIVO past earnings result in our data set was 0.660/share posted in Q2 2022, while the lowest was in Q1 2020 when VIVO posted 0.100/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q2 2022 when VIVO reported 0.11B in revenue, while the quarter with the lowest revenue in our data set was Q4 2012 at 43.70M of revenue.

  Suggested answer: There are 41 VIVO past earnings results in our data set.

On this page we presented the VIVO past earnings date information for Meridian Bioscience. Reviewing that VIVO Past Earnings for the company, we see that the highest past earnings result in our data set was in Q2 2022, when VIVO posted adjusted EPS of 0.660/share. Meanwhile the lowest VIVO past earnings result was in Q1 2020, when VIVO posted adjusted EPS of 0.100/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q2 2022 when VIVO reported 0.11B in revenue, while the smallest revenue quarter was Q4 2012 when VIVO reported 43.70M in revenue.

Any self directed investor doing their due diligence on VIVO or any other given stock can benefit from researching all of the Meridian Bioscience past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you to make it easy for investors to investigate Meridian Bioscience past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for VIVO. Thanks for visiting, and the next time you need to research VIVO past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Top Ten Hedge Funds Holding GPE, TYPE Options Chain, Funds Holding INTZ.


VIVO Past Earnings | | Copyright © 2020 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.